← Back to Search

Monoclonal Antibodies

AVB-S6-500 for Ovarian Cancer

Phase 1
Waitlist Available
Research Sponsored by Aravive, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 months
Awards & highlights

Study Summary

This trial is testing a new cancer drug, AVB-S6-500, to see if it is safe and effective when used with other cancer drugs to treat ovarian cancer that has come back after treatment.

Eligible Conditions
  • Ovarian Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Anti-tumor activity of AVB-S6-500 in combination with PLD
Anti-tumor activity of AVB-S6-500 in combination with Pac
Incidence of Adverse Events (AEs)
Secondary outcome measures
Anti-drug antibody (ADA) titers
CA-125 response rate
Disease control rate
+9 more

Trial Design

6Treatment groups
Experimental Treatment
Active Control
Group I: Phase 2: AVB-S6-500+PacExperimental Treatment2 Interventions
Group II: Phase 2: AVB-S6-500+PLDExperimental Treatment2 Interventions
Group III: Phase 1b: AVB-S6-500+PacExperimental Treatment2 Interventions
Group IV: Phase 1b: AVB-S6-500+PLDExperimental Treatment2 Interventions
Group V: Phase 2: Placebo+PacActive Control2 Interventions
Group VI: Phase 2: Placebo+PLDActive Control2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Paclitaxel (Pac)
2018
Completed Phase 1
~60
Pegylated liposomal doxorubicin (PLD)
2015
Completed Phase 3
~640
AVB-S6-500
2018
Completed Phase 1
~100

Find a Location

Who is running the clinical trial?

Aravive, Inc.Lead Sponsor
8 Previous Clinical Trials
571 Total Patients Enrolled
Mary Jo BakerStudy DirectorAravive Biologics Inc
Amy FrankeStudy DirectorAravive, Inc.
3 Previous Clinical Trials
472 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
2018. "Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03639246.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top